[ZURICH] Swiss drugmaker Novartis on Friday won US approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time...

[BENGALURU] Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Japan-headquartered Takeda Pharmaceutical Company's dry eye drug Xiidra for an upfront payment of US$3.4 billion to...

[MINNEAPOLIS] Novartis AG's Zolgensma, a gene therapy under review for treating children with a rare inherited disease that typically kills before the age of 2, also appears promising for a...

[ZURICH] Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.

[ZURICH] Novartis on Monday exercised its option to license an RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as the Swiss company aims to surround its heart-failure blockbuster...

[ZURICH] Switzerland's Roche and Novartis and other drugmakers are touting new treatments for a blindness-causing disease that hits millions of older people, as patent expiries are set to open up...

NOVARTIS AG is looking to strengthen its ties with tech startups as giants such as Apple Inc, Google and Amazon.com Inc advance rapidly into the healthcare field.

[LONDON] Novartis AG is looking to strengthen its ties with tech startups as giants like Apple Inc., Google and Amazon.com Inc. advance rapidly into the healthcare field.

[ZURICH] Drugmaker Novartis will cut about 2,200 jobs in Switzerland over the next four years as it consolidates production and shifts positions elsewhere to boost profitability, the Swiss company...